Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7384158 | 0.86 | KMT2A (0.59) | KMT2AMEN1GRIN2BALDH1A1NPSR1 | |
| SCHEMBL3047836 | 0.85 | GRIN2B (0.54) | KMT2AMEN1GRIN2BALDH1A1NPSR1 | |
| SCHEMBL61861 | 0.84 | KMT2A (0.66) | KMT2AMEN1GRIN2BALDH1A1NPSR1 | |
| SCHEMBL19942398 | 0.84 | KMT2A (0.57) | KMT2AMEN1GRIN2BALDH1A1NPSR1 | |
| SCHEMBL542683 | 0.82 | MEN1 (0.58) | KMT2AMEN1GRIN2BALDH1A1NPSR1 | |
| SCHEMBL3614455 | 0.81 | MEN1 (0.58) | KMT2AMEN1GRIN2BNPSR1SMN1; SMN2 | |
| SCHEMBL12551274 | 0.81 | MEN1 (0.54) | KMT2AMEN1GRIN2BALDH1A1NPSR1 | |
| SCHEMBL3039444 | 0.80 | SMN1; SMN2 (0.52) | KMT2AMEN1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL4484409 | 0.80 | GRIN2B (0.47) | KMT2AMEN1GRIN2BALDH1A1P2RX4 | |
| SCHEMBL31517046 | 0.80 | MEN1 (0.51) | KMT2AMEN1GRIN2BALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592360-B2 | Parkinson's disease, Alzheimer's disease, migraine, epilepsy, and pain | MERCK & CO., INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592360-B2 | Parkinson's disease, Alzheimer's disease, migraine, epilepsy, and pain | MERCK & CO., INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592360-B2 | Parkinson's disease, Alzheimer's disease, migraine, epilepsy, and pain | MERCK & CO., INC. (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1648882-B1 | 3-FLUORO-PIPERIDINES AS NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1648882-B1 | 3-FLUORO-PIPERIDINES AS NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070149568-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | MERCK SHARP & DOHME LLC | 2007-06-28 | — | — | US | disclosed |
| US-20070149568-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | MERCK SHARP & DOHME LLC | 2007-06-28 | — | — | US | disclosed |
| US-20070149568-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | MERCK SHARP & DOHME LLC | 2007-06-28 | — | — | US | disclosed |
| CN-1798744-A | 3-fluoro-piperidines as NMDA/NR2B antagonists. | MERCK & CO INC (US) | 2006-07-05 | — | — | CN | disclosed |
| EP-1648882-A1 | 3-FLUORO-PIPERIDINES AS NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2004108705-A1 | 3-FLUORO-PIPERIDINES AS NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108705-A1 | 3-FLUORO-PIPERIDINES AS NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149568-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | GRIN2B, GRIN1, GRIN2A | KMT2A 1463/4885MEN1 1344/4885GRIN2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.